A DOx compound is a substituted amphetamine bearing 2,5-dimethoxy substitutions on the aromatic ring and a variable group at the 4-position, producing long-duration psychedelic effects with a pronounced stimulant component.[1] The class is defined by this shared chemical scaffold — "DO" encoding the 2,5-dimethoxyamphetamine core, "x" the variable 4-position substituent — and membership is tight and structurally precise.
The class spans halogen-substituted members DOB (bromo), DOC (chloro), and DOI (iodo), and alkyl-substituted members DOM (methyl), DOET (ethyl), and DOPR (propyl).[2] The 4-position group shifts potency, duration, and intrinsic efficacy at the shared serotonin-receptor targets, but every member converges on the same qualitative pharmacological profile.
DOx compounds produce visual and perceptual effects qualitatively similar to other serotonergic psychedelics, layered over amphetamine-like arousal, peripheral sympathomimetic load, and a characteristically slow onset and long duration.[3] The class arose from Alexander Shulgin's systematic mapping of 4-position substitutions beginning in the 1960s and is encountered today almost entirely in research and unsupervised recreational settings; at high exposure the same scaffold drives severe vasoconstriction and sympathomimetic toxicity.[4]
Pharmacology
DOx members converge on a single pharmacological signature: selective partial agonism at serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with the psychedelic phenomenology attributed specifically to 5-HT2A activation on cortical pyramidal neurons.[3]
Unlike classical amphetamines, DOx compounds are not monoamine releasers and do not appreciably inhibit reuptake; the amphetamine backbone instead lengthens duration and contributes a sympathomimetic tone layered over a serotonergic core.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| 5-HT2A partial agonism | DOI, DOB, DOM | Activates Gq/11–phospholipase C signaling on cortical pyramidal neurons, altering glutamate release and cortical excitability[3] |
| 5-HT2B agonism | Halogen-substituted members (DOB, DOC, DOI) | Drives potent arterial smooth-muscle contraction — the basis of the class's vasoconstrictive toxicity[1] |
| 5-HT2C agonism | Class-wide | Contributes mood, anxiety, and appetite effects layered over the 5-HT2A psychedelic core |
The shared scaffold also enforces a shared structure-activity logic. The 2,5-dimethoxy pattern is essential for high receptor affinity, and within the 4-position series binding affinity tracks halogen size and lipophilicity — iodo, bromo, and chloro members carry higher 5-HT2A affinity than the shorter alkyl variants, while halogenation also appears to raise intrinsic efficacy at downstream signaling.[1] The α-methyl group that distinguishes the amphetamine backbone from the parent 2C-x phenethylamines slows metabolic degradation and is the structural basis of the class's long duration.
The endpoint that matters more than the molecular route is the combined serotonergic-plus-sympathomimetic load. Different 4-position groups reach that endpoint with different potencies and efficacies, but the qualitative profile — psychedelic effects driven by 5-HT2A, vasoconstrictive risk driven by 5-HT2B, stimulant character from the amphetamine backbone — is shared across every member.
Substances
The class is illustrated by members spanning the halogen and alkyl 4-position series:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| DOM | 4-alkyl | Founding member of the class, first synthesized by Shulgin in the 1960s and historically distributed as "STP"[2] |
| DOI | 4-halogen | Principal pharmacological tool of the class; provided the [¹²⁵I]DOI radioligand central to 5-HT2A receptor mapping[1] |
| DOB | 4-halogen | Highest reported intrinsic 5-HT2 efficacy in the class; associated with severe and fatal human overdose cases[4] |
| DOC | 4-halogen | Documented in fatal recreational case literature; illustrative of the detection challenge posed by uncommon DOx members[5] |
| DOET | 4-alkyl | Longer alkyl chain than DOM; shares the class profile with less clinical documentation |
| DOPR | 4-alkyl | Propyl chain extends lipophilicity; produces class-typical behavioural effects in animal studies |
These members differ in receptor affinity, intrinsic efficacy, and peak potency, but each produces the same qualitative combination of long-duration psychedelic effects, stimulant arousal, and sympathomimetic load.
Subjective Effects
The class produces a distinctive psychedelic-stimulant profile layered onto a slow onset and unusually long duration. Onset after oral exposure characteristically takes hours, reflecting the amphetamine backbone's slower absorption and the metabolic stability conferred by the α-methyl group; the full course extends through most of a day, and residual stimulation and insomnia can persist beyond the psychedelic peak.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Mild perceptual sharpening, elevated arousal, suppressed fatigue, and a sense of bodily activation |
| Moderate–high | Geometric visuals, altered colour intensity, object morphing, intensified emotional content, altered time sense, elevated heart rate and blood pressure, jaw tension, pupil dilation, and insomnia |
| High | Frank hallucinations, depersonalization, severe anxiety or panic, agitation, marked sympathomimetic load, and progressive peripheral vasoconstriction[5] |
The same serotonergic and sympathomimetic axes drive both the sought-after psychedelic effects and the class's most dangerous physical effects, and the margin between them narrows sharply as exposure rises. The slow onset compounds this hazard: case-report literature documents users who redosed before initial effects emerged, producing inadvertent overdose.[4]
Safety
Risk profile
The defining acute danger of the DOx class is severe peripheral vasoconstriction combined with sympathomimetic cardiotoxicity. At high exposure, 5-HT2B-driven arterial spasm can progress to tissue ischemia and necrosis, while concurrent tachycardia, hypertension, and convulsions raise the risk of cardiac arrhythmia, metabolic acidosis, and multi-organ failure.[4][5] Severe presentations may not appear until several hours after ingestion and have required prolonged hospital management.
Vasoconstrictive risk appears highest for the halogen-substituted members and particularly for DOB, which carries the highest reported intrinsic efficacy at 5-HT2 receptors in the class.[1] The slow onset is a class-wide hazard in its own right: users who redose before the initial dose has taken effect can compound exposure to dangerous levels, a pattern documented across the fatal and near-fatal case reports.[4]
Polydrug combinations sharpen these risks. Co-use with other serotonergic agents raises serotonin-syndrome risk; co-use with other stimulants amplifies cardiovascular load. Standard hospital immunoassay drug screens do not reliably detect DOx compounds, and confirmatory GC-MS or LC-MS/MS is required — a gap that has delayed identification in documented overdose presentations and shifted management toward empirical treatment of the sympathomimetic syndrome.[5][6]
Tolerance & dependence
Tolerance to DOx effects develops rapidly. Animal studies document a measurable reduction in the standard 5-HT2A behavioural response within twenty-four hours of a single DOI exposure, with frontal-cortex 5-HT2A receptor downregulation as the proposed mechanism.[7] Tolerance typically resolves over a week or two of abstinence.
Cross-tolerance is functionally complete across the class and extends to other serotonergic psychedelics. A user tolerant to one DOx member is substantially tolerant to the others, and to lysergamides and tryptamines, because the underlying receptor adaptation is shared.[7]
Physical dependence and a withdrawal syndrome are not documented for the DOx class. The rapid functional tolerance tends to make repeat dosing progressively unrewarding, and the receptor mechanism does not engage the dopaminergic reinforcement pathway that drives classical stimulant dependence.[3] Psychological habituation is theoretically possible but is not described as a clinically significant problem in the available literature.
Recovery
Because the class does not produce physical dependence or a medically dangerous withdrawal, recovery does not require supervised detoxification. The recovery-relevant concerns are different: persistent perceptual disturbances after heavy exposure, psychological integration after long and intense experiences, and clinical follow-up for anyone who suffered an ischaemic or cardiovascular event during acute toxicity. A clinician, a harm-reduction service, or an integration-focused therapist is the appropriate first step for any of these.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2]
- [3]
- [4]
- [5]^abcdBarnett RY, Baker DD, Kelly NE, McGuire CE, Fassette TC, Gorniak JM (2014) A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report. — Journal of Analytical Toxicology doi:10.1093/jat/bku087
- [6]^Ovaska H, Viljoen A, Puchnarewicz M, Button J, Ramsey J, Holt DW, Dargan PI, Wood DM (2008) First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening. — European Journal of Emergency Medicine doi:10.1097/mej.0b013e3282fc765b